# US 2024/0002938 A1 · System and method for cleaning noisy genetic data and determining chromosome copy number

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002938 A1
- Document ID: US20240002938A1
- Status: Published application
- Kind: A1
- Application number: 18/243,569
- Filed: 2023-09-07
- Published: 2024-01-04
- Earliest claimed: 2005-07-29
- Assignees: Natera, Inc.
- Applicants: Natera, Inc.
- Inventors: Matthew RABINOWITZ; Milena BANJEVIC; Zachary DEMKO; David JOHNSON; Dusan KIJACIC; Dimitri PETROV; Joshua SWEETKIND-SINGER; Jing XU
- Web page: https://patentgrep.com/patent/US20240002938A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 20/10: Ploidy or copy number detection
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6855: Ligating adaptors
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B 40/20: Supervised data analysis
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Disclosed herein is a system and method for increasing the fidelity of measured genetic data, for making allele calls, and for determining the state of aneuploidy, in one or a small set of cells, or from fragmentary DNA, where a limited quantity of genetic data is available. Poorly or incorrectly measured base pairs, missing alleles and missing regions are reconstructed using expected similarities between the target genome and the genome of genetically related individuals. In accordance with one embodiment, incomplete genetic data from an embryonic cell are reconstructed at a plurality of loci using the more complete genetic data from a larger sample of diploid cells from one or both parents, with or without haploid genetic data from one or both parents. In another embodiment, the chromosome copy number can be determined from the measured genetic data, with or without genetic information from one or both parents.

## Claims

### Claim 1

A method for preparing non-naturally occurring compositions of amplified DNA derived from a biological sample obtained from a second individual, wherein the biological sample comprises DNA from a first individual, the method comprising:
(a) extracting cell-free DNA from the biological sample, thereby resulting in a first non-naturally occurring composition that may include cell-free DNA from the said first individual and the said second individual, wherein the biological sample is a maternal blood sample, and wherein the first individual is a fetus;
(b) preparing a second non-naturally occurring composition of amplified DNA by amplifying a plurality of target loci on the cell-free DNA extracted from the biological sample to generate amplified DNA, thereby resulting in a second non-naturally occurring composition that may include amplification products derived from cell-free DNA from the said first individual and the said second individual.

### Claim 2 (depends on 1)

The method of claim 1, further comprising analyzing the non-naturally occurring second composition of amplified DNA by sequencing the amplified DNA using sequencing-by-synthesis to obtain genetic data of the plurality of target loci, and assigning to the first individual the most likely genetic data for DNA from the first individual based on allele frequencies in the genetic data at the plurality of target loci.

### Claim 3 (depends on 1)

The method of claim 1, wherein the target loci are polymorphic loci.

### Claim 4 (depends on 1)

The method of claim 1, wherein the target loci are SNP loci.

### Claim 5 (depends on 1)

The method of claim 1, wherein the target loci are on a plurality of chromosomes.

### Claim 6 (depends on 1)

The method of claim 1, wherein the amplifying comprises targeted PCR.

### Claim 7 (depends on 1)

The method of claim 1, wherein the amplifying comprises targeted PCR and universal PCR.

### Claim 8 (depends on 1)

The method of claim 1, wherein the sequencing-by-synthesis comprises clonal amplification of the amplified DNA and measurement of sequences of the clonally amplified DNA.

### Claim 9 (depends on 1)

The method of claim 1, wherein the genetic data produced by sequencing is noisy and comprises allele drop out errors.

### Claim 10 (depends on 1)

The method of claim 1, wherein the genetic data produced by sequencing is noisy and comprises measurement bias.

### Claim 11 (depends on 1)

The method of claim 1, wherein the genetic data produced by sequencing is noisy and comprises incorrect measurements.

### Claim 12 (depends on 1)

The method of claim 1, further comprising normalizing the genetic data for differences in amplification and/or sequencing efficiency between the target loci.

### Claim 13 (depends on 4)

The method of claim 4, wherein the target loci comprises about 70-500 SNPs.

### Claim 14 (depends on 4)

The method of claim 4, wherein the confidence that each SNP is correctly called is at least 95%.

### Claim 15 (depends on 4)

The method of claim 4, wherein the confidence that each SNP is correctly called is at least 99%.

### Claim 16

A method for preparing non-naturally occurring compositions of amplified DNA derived from a biological sample obtained from a second individual, wherein the biological sample comprises DNA from a first individual, the method comprising
(a) extracting cell-free DNA from the biological sample, thereby resulting in a non-naturally occurring first composition that may include cell-free DNA from the said first individual and the said second individual, wherein the biological sample is a maternal blood sample, and wherein the first individual is a fetus;
(b) preparing a non-naturally occurring second composition of amplified DNA by performing targeted PCR to amplify a plurality of SNP loci on the cell-free DNA extracted from the biological sample to generate amplified DNA, thereby resulting in a non-naturally occurring second composition that may include amplification products derived from cell-free DNA from the said first individual and the said second individual, wherein the SNP loci are located on a plurality of chromosomes.

### Claim 17 (depends on 16)

The method of claim 16, further comprising analyzing the non-naturally occurring second composition of amplified DNA by sequencing the amplified DNA using sequencing-by-synthesis to obtain genetic data of the plurality of SNP loci, wherein the sequencing-by-synthesis comprises clonal amplification of the amplified DNA and measurement of sequences of the clonally amplified DNA, and assigning to the first individual the most likely genetic data for DNA from the first individual based on allele frequencies in the genetic data at the plurality of SNP loci.

### Claim 18 (depends on 16)

The method of claim 16, wherein the target loci comprises about 70-500 SNPs.

### Claim 19 (depends on 16)

The method of claim 16, wherein the confidence that each SNP is correctly called is at least 95%.

### Claim 20 (depends on 16)

The method of claim 16, wherein the confidence that each SNP is correctly called is at least 99%.
